EGFR and breast carcinoma: The race for a successful breast cancer treatmentintensified during the late 1990s and 2000s, resulting in the development ofinnovative anti-EGFR therapies in the last few years including both monoclonalantibodies (MoAbs) and small moleculetyrosine kinase inhibitors.